Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K.

The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology.

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space, where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.

Also Read: GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults

The acquisition also adds ‘Molecular Clamp,’ a technology stabilizing viral proteins in their native shape, enabling the immune system to recognize and respond to them more effectively.

The ...